Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Cell Immunol. 2021 Oct 14;370:104450. doi: 10.1016/j.cellimm.2021.104450

Fig. 1.

Fig. 1.

Therapeutic administration of DON reduces development and severity of SK and angiogenesis after HSV-1 ocular infection. Effect of therapeutic administration (from day 6 PI) of DON (0.3 mg/kg) on SK severity (A) in C57BL/6 at day 15 PI (n=12). Degree of angiogenesis (B) in C57BL/6 mice was recorded from individual eyes on day 15 PI (n=12). Data analyses were done by-a paired Wilcoxon-signed rank test and represented with median.